Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D.
Rousseau RF, et al. Among authors: bowman lc.
Blood. 2003 Mar 1;101(5):1718-26. doi: 10.1182/blood-2002-08-2493. Epub 2002 Oct 24.
Blood. 2003.
PMID: 12406881
Free article.
Clinical Trial.